Global Irritable Bowel Syndrome IBS Market 2018

Over the next five years, Planet Market Reports projects that Irritable Bowel Syndrome IBS will register a 16.3% CAGR in terms of revenue, reach US$ 6530 million by 2023, from US$ 2640 million in 2017.

December 2018

Irritable Bowel Syndrome IBS Consumption Market | Forecast 2018-2023

In this report, Planet Market Reports covers the present scenario with the base year being 2017 and the growth prospects of global Irritable Bowel Syndrome IBS market for 2018-2023.

Irritable bowel syndrome IBS is defined as recurrent abdominal pain or discomfort that occurs in association with altered bowel habits over a period of at least 3 months. The disorder is classified into three main subtypes, according to the predominant bowel habits presented: constipation-predominant IBS IBS-C , diarrhea-predominant IBS IBS-D , and mixed-presentation IBS IBS-M . IBS is among the most common gastrointestinal disorders, with an estimated pooled international IBS prevalence rate of about 11.2%.

 

 

Currently, the IBS treatment market is naïve and underpenetrated, with 4 products indicated for IBS in the market. These include the IBS-C therapies, Amitiza lubiprostone, Sucampo/Takeda and Linzess linaclotide, Ironwood/Allergan/Astellas ; and the IBS-D therapies, Lotronex Sebela Pharmaceuticals and Irribow ramosetron, Astellas . Antidepressants and antibiotics mainly Xifaxan rifaximin , Valeant are also used off-label to treat IBS.

The IBS treatment market is characterized by significant unmet needs, which include the need for products with improved efficacy, products for the treatment of the IBS-D and IBS-M subtypes, and products that effectively address IBS symptoms, such as abdominal pain and bloating, as well as the requirement for the improved diagnosis of IBS. As a result, there are significant opportunities in the uncrowded IBS therapeutics market.

Over the next five years, Planet Market Reports projects that Irritable Bowel Syndrome IBS will register a 16.3% CAGR in terms of revenue, reach US$ 6530 million by 2023, from US$ 2640 million in 2017.
This report presents a comprehensive overview, market shares, and growth opportunities of Irritable Bowel Syndrome IBS market by product type, application, key manufacturers and key regions.
To calculate the market size, Planet Market Reports considers value and volume generated from the sales of the following segments:

Segmentation by product type:
IBS-D Drug
IBS-C Drug
Other

Segmentation by application:

Women
Men

 Buy now and get a Beneficial 30% off on this report @ https://www.planetmarketreports.com/reports/20182023-global-irritable-bowel-syndrome-ibs-consumption-market-9810